AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
 To Contact Brower Piven Before The Lead Plaintiff Deadline - EconoTimes)
STEVENSON, Md., March 17, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos” or the “Company”) securities during the period between February 7, 2014 and February 21, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 15, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Argos securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s Arcelis immunotherapy technology platform was not viable and the ADAPT phase 3 trial for the treatment of metastatic renal cell carcinoma was likely to be discontinued.
According to the complaint, following a February 22, 2017 announcement that the Independent Data Monitoring Committee recommended that the ADAPT trial be discontinued for futility, the value of Argos shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Argos securities purchased on or after February 7, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]
